Vascular leiomyosarcoma originating from the right ovarian vein: a case report and literature review

Takuro Hirano 1*, Hiroshi Okumura 1, Satoru Maeda 1, Mario Shimada 1, Akira Imakiire 1, Kanro Makisumi 1, Michiyo Higashi 2 and Shoji Natsugoe 3

Abstract

Background: Primary leiomyosarcoma (LMS) of vascular origin is a rare lesion, and patients with LMS of vascular origin have poorer prognoses than patients with LMS of other origins. The inferior vena cava is the most commonly affected vessel and accounts for 60% of all vascular cases. However, LMS originating from the ovarian vein is extremely rare, and we are only aware of 15 reported cases. Therefore, we report our experience with a case of LMS originating from the right ovarian vein and review the related literature.

Case presentation: A 71-year-old Japanese woman with no symptoms was admitted to our hospital because of abnormal findings in a routine abdominal ultrasonography check-up. Contrast-enhanced computed tomography of the abdomen revealed a well-defined, lobulated solid mass with a diameter of 5.5 cm in the right retroperitoneal space. The mass exhibited relatively low uptake during 18F-fluorodeoxyglucose positron emission tomography. Based on these findings, the differential diagnosis included a retroperitoneal tumor, such as a desmoid tumor, leiomyoma, LMS, and malignant mesothelioma. Operative findings confirmed that the mass had originated from the right ovarian vessels, and en bloc excision was performed for the mass and the right ovarian vessels. The final pathological diagnosis was LMS originating from the right ovarian vein, and the surgical resection margins were free from tumor cells. After histological findings confirmed the LMS diagnosis, the patient underwent adjuvant radiation therapy and has not exhibited signs of local recurrence or metastasis in the 6 months after surgery.

Conclusions: We encountered a 71-year-old woman with LMS originating from her right ovarian vein. The prognosis of vascular LMS is generally poor. Therefore, careful follow-up will be required for our patient.

Keywords: Leiomyosarcoma, Ovarian vein, Vascular leiomyosarcoma, Retroperitoneal sarcoma

Background

Leiomyosarcoma (LMS) is a mesenchymal tumor of smooth muscle origin. However, primary LMS of vascular origin is a rare lesion that represents < 1/100,000 of malignant tumors. Patients with LMS of vascular origin have poorer prognoses than patients with LMS of other origins [1]. The inferior vena cava is the most commonly affected vessel, accounting for 60% of all vascular cases [2], followed by the large central veins and the long saphenous veins [2, 3]. The ovarian veins are an extremely rare site of origin of LMS, with only 15 reported cases [2, 4–17]. Therefore, we report our experience with a case of primary LMS originating from the right ovarian vein and review the related literature.

Case presentation

A 71-year-old previously healthy Japanese woman with no symptoms was admitted to our hospital because of abnormal findings in a routine abdominal ultrasonography check-up, which supported a suspicion of main pancreatic duct dilatation and gallbladder polyps. Physical examination revealed a palpable mass with good mobility in the right lower abdomen. The laboratory findings were all within the normal ranges. Contrast-

* Correspondence: hira-2323@wb3.so-net.ne.jp
1Department of Surgery, Southern Region Hospital, Midorimachi 220, Makurazaki, Kagoshima 898-0011, Japan
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
enhanced computed tomography (CT) of the abdomen revealed no abnormal findings in the pancreas and gallbladder but revealed a well-defined, lobulated solid mass with a diameter of 5.5 cm in the right retroperitoneal space (Fig. 1a, b). Magnetic resonance imaging (MRI) of the abdomen was performed: on T1-weighted imaging, the mass showed diffuse low intensity (Fig. 2a), and on T2-weighted imaging, the mass showed uniform low intensity (Fig. 2b). On gadolinium enhancement, the mass showed heterogeneous and incremental enhancement (Fig. 2c, d). On 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), the mass had relatively low uptake, with a maximum standardized uptake value (SUVmax) of 2.4 (Fig. 3). Based on these findings, the differential diagnosis included a retroperitoneal tumor, such as a desmoid tumor, leiomyoma, LMS, and malignant mesothelioma.

Exploratory laparotomy was performed through a median incision, and the operative findings confirmed that the mass was attached and connected to the right ovarian vessels. The mass was slightly adhered to the ureter, but there were no signs of invasion to the other adjacent organs. Because the mass appeared to originate from the right ovarian vessels, en bloc excision of the mass and
right ovarian vessels was performed. The surgical specimen consisted of a white solid tumor (5.5 cm × 4.5 cm) (Fig. 4a, b); the ovarian vessels passed through the dorsal side of the tumor (Fig. 4b). Microscopically, atypical spindle cells revealed interlacing fascicles without necrosis (Fig. 5a) and that the tumor cells connected with the right ovarian vein (Fig. 5b) with 50 mitoses per 50 high-power fields (HPF) (Fig. 5c). On immunohistochemical staining, the tumor cells were found to be diffusely positive for α-smooth muscle actin (α-SMA) (Fig. 5d), desmin (Fig. 5e), and caldesmon (Fig. 5f) and negative for CD34, S100, c-kit, MDM2, and cyclin-dependent kinase 4 (CDK4). These findings supported a diagnosis of LMS. The surgical resection margins were free from tumor cells. The patient's postoperative course and recovery were uneventful. Based on the histological diagnosis of LMS, the patient underwent adjuvant radiation therapy (total dose, 50.4 Gy in 25 fractions) and has not exhibited signs of local recurrence or metastasis in the 6 months after surgery.

Discussion

LMS is the second most common retroperitoneal sarcoma among adults [18]. Retroperitoneal LMS originates from smooth muscles within the retroperitoneum, such as the wall of the retroperitoneal veins or embryonic remnants [19]. The vena cava is the most commonly affected vessel in vascular LMS cases, and these cases have been well described. The ovarian vein is the eighth most commonly affected vessel in cases of vascular LMS that do not originate from the vena cava [20]. Therefore, LMS originating from the ovarian vein is extremely rare, and we are only aware of 15 reported cases [2, 4–17]. Table 1 summarizes the 15 reported cases and our case. Median patient age at diagnosis was 55 years (range, 37–78 years) and median maximum tumor size was 7.5 cm (range, 3–28 cm). Twelve of the 15 reported cases (80%) involved nonspecific symptoms, including abdominal pain (6 cases), abdominal mass (4 cases), abdominal distension (1 case), and abdominal discomfort (1 case). Two patients complained of symptoms related to the tumor’s invasion of the ureter (repeated pyelonephritis and back pain). Our patient is the only one to have no symptoms at diagnosis.

Tumors originating from the left ovarian vein and from the right ovarian vein have been reported in 6 (40%) and 9 (60%) cases, respectively.

Three major growth patterns have been reported for retroperitoneal LMS: completely extravascular (extraluminal, 62% of cases), completely intravascular (intraluminal, 5% of cases), and a combination of extraluminal and intraluminal patterns (mixed, 33% of cases) [21]. Cases of LMS with an extraluminal pattern are usually diagnosed late in their course, while LMS cases with intraluminal and mixed patterns are more likely to show early symptoms that depend on the affected vein [21]. Among 9 reports on LMS originating from the ovarian veins, extraluminal patterns were observed in 4 cases (44.4%) and mixed patterns in 5 cases (55.6%), with no cases involving intraluminal patterns. In the present case, the growth pattern was considered to be extraluminal because the ovarian vein passed through the dorsal side of the tumor.
and because no tumor cells had invaded the ovarian vein lumen.

Based on these presentations, contrast-enhanced CT is especially useful for establishing the preoperative diagnosis and for determining the tumor extent and boundaries before starting surgery [15]. Previous reports have indicated that CT typically reveals a large mass with heterogeneous contrast in the longitudinal orientation, which replaces the normal ovarian vein as well as cystic and necrotic components and vascular hypertrophy [8, 15, 22]. Additional information regarding the lesion can be obtained using MRI [9, 10]. Previous reports have also indicated that increased uptake during FDG-PET provided high accuracy for diagnosing LMS [23]. FDG-PET can be used to diagnose a retroperitoneal mass as an LMS originating from an ovarian vein [10]. Among the 13 cases of LMS originating from the ovarian vein, CT was performed in 13 (100%), MRI was performed in 5 (38.5%), and PET was performed in 3 (23.1%); preoperative diagnosis was made in 4 cases (30.8%). In our case, contrast-enhanced CT revealed a solid mass with no necrosis, which is less common for extraluminal LMS but typical for smaller retroperitoneal tumors [21]. Furthermore, the mass exhibited relatively low uptake during FDG-PET, which made it difficult to establish a preoperative diagnosis of LMS. In our case, the tumor was detected early, was small in size, and had a low mitotic rate. Therefore, the findings (no necrosis and low FDG accumulation) were not typical.

In retroperitoneal sarcoma cases, 60% of resected adjacent organs were found to be microscopically invaded by the tumor [10]. En bloc resection with histopathologically free margins is essentially the only procedure that can result in a good prognosis [15, 24]. However, even after complete tumor resection, patients with retroperitoneal sarcoma have poor prognoses, based on a > 50% recurrence rate and a 5-year survival rate of 52–65% [18, 25, 26]. Thus, in cases of large soft tissue sarcomas with high-grade histological findings, radiation therapy and chemotherapy are considered before or after surgery to lower the risk of local recurrence and distant metastases [27, 28]. Therefore, we performed adjuvant radiation therapy to lower the risk of local recurrence. If LMS originating from the ovarian vein had been diagnosed preoperatively in our case, comprehensive treatment with a combination of en block excision of the tumor and ovarian vessels and adjuvant therapy would have been recommended.

Metastasis is identified at diagnosis in 12% of cases of vascular LMS that did not originate from the vena cava [20], although none of the reported cases of LMS originating from the ovarian vein involved metastasis at the initial diagnosis. All of these patients underwent radical resection that did or did not involve the adjacent organs; 50% of patients (7/14) received adjuvant radiation therapy (28.6%, 4/14) or chemotherapy (21.4%, 3/14). Tumor recurrence after radical resection was observed in 50% of cases (6/12). Distant metastasis (41.7%, 5/12) was
more frequent than local recurrence (8.3%, 1/12), and the popular metastatic sites were the lung (36.4%, 4/11) and liver (27.2%, 3/11). These findings are consistent with the previously reported characteristics of retroperitoneal LMS [18, 29]. Median interval to tumor recurrence was 12 months (range, 2–17 months), and the shortest and longest recurrence-free periods were 2 months and 17 months, respectively; therefore, surveillance every 3 months for at least 2 years is recommended. Table 2 shows the correlation between tumor recurrence and clinicopathological factors based on the literature. Interestingly, all patients with > 20 mitoses/10 HPF eventually developed recurrence after radical resection, whereas no metastasis was detected in cases with < 20 mitoses/10 HPF. Thus, a low mitotic rate may predict a favorable prognosis; however, for cases without recurrence, the median observation period was only 13.5 months, which is too short for an accurate evaluation of the patients’ prognosis. In addition, younger age and tumor resection involving the adjacent organs may be potential risk factors for recurrence; however, analysis of recurrence showed no significant risk factors, which may be due to the small cohort size.

In the present case, careful follow-up will be required, despite the low mitotic rate of 10 mitoses/10 HPF, which would predict a good outcome based on the previous sentence.

**Conclusion**

We encountered a 71-year-old woman with rare vascular LMS originating from the right ovarian vein. Although the prognosis of LMS originating from the ovarian vein is obscured by its rarity and short-term observation data, the prognosis of vascular LMS is generally poor. Therefore, careful follow-up will be required for our patient.

**Abbreviations**

CDK4: Cyclin-dependent kinase 4; CT: Computed tomography; FDG-PET: 18F-fluorodeoxyglucose positron emission tomography; HPF: High-power field; LMS: Leiomyosarcoma; MRI: Magnetic resonance imaging; α-SMA: α-smooth muscle actin

**Acknowledgements**

Not applicable

---

**Table 1** Summary of leiomyosarcoma originated from the ovarian vein

| Case | 16 |
| --- | --- |
| Age (years)* (n = 16) | 55 (37–71) |
| Tumor size (cm)* (n = 15) | 7.5 (3–28) |
| Symptom (%) (n = 15) |  
| Abdominal pain | 6 (40) |
| Abdominal mass | 4 (26.7) |
| Pyelonephritis | 1 (6.7) |
| Abdominal distension | 1 (6.7) |
| Back pain | 1 (6.7) |
| Abdominal discomfort | 1 (6.7) |
| No symptom | 1 (6.7) |
| Side (%) (n = 15) |  
| Left:right | 6 (40):9 (60) |
| Growth pattern (%) (n = 9) | extra/intra/mixed | 4 (44.4)/0 (0)/5 (55.6) |
| Modality (%) (n = 13) | CT/MRI/PET | 13 (100)/5 (38.5)/3 (23.1) |
| Preoperative diagnosis (%) (n = 13) | Yes/no | 4 (30.8)/9 (69.2) |
| Surgery (%) (n = 16) |  
| Simple tumor excision | 2 (12.5) |
| En block | 5 (31.2) |
| En block with adjacent organs | 9 (56.3) |
| Adjuvant therapy (%) (n = 14) | Chemotherapy/radiotherapy/no | 3 (21.4)/4 (28.6)/7 (50.0) |
| Recurrence (%) (n = 12) | Yes/no | 6 (50.0)/6 (50.0) |
| Recurrence pattern (%) (n = 12) | Local recurrence/distant metastasis | 1 (8.3)/5 (41.7) |
| Metastatic site (%) (n = 11) | Lung/liver/others | 4 (36.4)/3 (27.2)/4 (36.4) |
| DFS (months)* (n = 11) | 12 (2–44) |
| Follow-up (months)* (n = 12) | 12 (2–44) |

*Median CT: Computed tomography, MRI: Magnetic resonance imaging, FDG-PET: 18F-fluorodeoxyglucose positron emission tomography

**Table 2** Correlation between tumor recurrence and clinicopathological factors in patients with leiomyosarcoma originating from ovarian vein

| n (%) | Tumor recurrence | P value |
| --- | --- | --- |
| Patient, n (%) | 12 | 6 (50.0) | 6 (50.0) |
| Age (range) | 12 | 51 (37–67) | 59.5 (56–78) |
| Side, n (%) | 11 |  
| Left | 6 (54.5) | 2 (40.0) | 4 (66.7) |
| Right | 5 (45.5) | 3 (60.0) | 2 (33.3) |
| Tumor size (range) | 11 | 16.5 (3–28) | 7.3 (5–21) |
| Growth pattern, n (%) | 9 |  
| Extra | 4 (44.4) | 1 (20.0) | 3 (75.0) |
| Mixed | 5 (55.6) | 4 (80.0) | 1 (25.0) |
| Surgery, n (%) | 12 |  
| Tumor resection (simple excision + en block) | 5 (41.7) | 1 (16.7) | 5 (83.3) |
| Tumor resection with adjacent organ | 7 (58.3) | 5 (83.3) | 1 (16.7) |
| Adjuvant therapy, n (%) | 11 |  
| Yes | 5 (45.5) | 2 (40.0) | 3 (50.0) |
| No | 6 (54.5) | 3 (60.0) | 3 (50.0) |
| Mitotic count, n (%) | 7 |  
| < 20/HPF | 4 (57.1) | 0 (0.0) | 4 (100) |
| ≥ 20/HPF | 3 (42.9) | 3 (100) | 0 (0.0) |

Statistical analyses of two groups were performed using χ²-test
Authors’ contributions
TH, SM, MS, AI, and KM participated in the surgery. TH and HO collected the data and consent and drafted the manuscript. SN performed the pathological examinations and participated in drafting the manuscript. SN participated in the design, coordination, and drafting of the manuscript. All authors read and approved the final manuscript.

Funding
We declare that each author received no funding for this study.

Availability of data and materials
All related data are included within the article.

Ethics approval and consent to participate
Not applicable

Consent for publication
The patient consented to the publication of this case and her identity has been protected.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Surgery, Southern Region Hospital, Midorigamichi 220, Makurazaki, Kaga0shima 898-0011, Japan. 2Department of Pathology, Kagoshima University Hospital, Sakuragaoka 8-35-1, Kaga0shima 890-8520, Japan. 3Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka 8-35-1, Kaga0shima 890-8520, Japan.

Received: 4 June 2019 Accepted: 19 July 2019

Published online: 24 July 2019

References

1. Italiano A, Toulmonde M, Stoeckle E, Kind M, Kantor G, Coindre JM, et al. Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin. Ann Oncol. 2010;21:1915–21.
2. Ozsinn C, Giovicki P, van Heerden JA, Nagorney DM, Paiolero PC, Johnson CM, et al. Primary venous leiomyosarcoma: a rare but lethal disease. J Vasc Surg. 1992;15:595–603.
3. Kevorkian J, Cento CP. Leiomyosarcoma of large arteries and veins. Surgery. 1973;73:390–400.
4. Honore LH, Robins RE, Taylor RH. Leiomyosarcoma of the right ovarian vein: a case report. Angiology. 1977;28:285–8.
5. Kawai K, Horiiuchi H, Fildoro N, Akaza H, Koiso K. Leiomyosarcoma of the ovarian vein: an unusual cause of severe abdominal and flank pain. Int J Urol. 1996;3:234–6.
6. Iannelli A, Karrimjee BS, Fabiani P, Liolos J, Allavone J, Gugennheim J. Leiomyosarcoma of the ovarian vein: report of a case. Am J Surg. 2009;197:e36–41.
7. Chiarelli M, Presi E, Mancini R, Fattori S, Galaiotto C, Secchia M. Leiomyosarcoma of the right ovarian vein. Am J Surg. 2009;197:e36–7.
8. Kim SH, Kwon HJ, Cho JH, Lee SW, Rha SH, Choi J, et al. Atypical radiological features of a leiomyosarcoma that arose from the ovarian vein and mimicked a vascular tumour. Br J Radiol. 2010;83:e95–7.
9. Yang SH, Chien JC, Chen CL, Chan WP. Leiomyosarcoma of ovarian vein compression as a cause of hydroperitoneum. Eur J Gynaecol Oncol. 2011;32:336–8.
10. Tissyschi H, Yoshida Y, Kurokawa T, Kotsuji F. Diagnosis and management of leiomyosarcoma arising from ovarian vein: case report and literature review. J Obstet Gynaecol Res. 2012;38:466–70.
11. Saigusa S, Ohi M, Inoue Y, Kusunoki M. Preoperative diagnosis by three-dimensional angiography of a leiomyosarcoma arising from the left ovarian vein. BMJ Case Rep. 2013. https://doi.org/10.1136/bcr-2013-008823.
12. Nakayama R, Takazawa I, Maruyama R, Kawaara T, Hara N, Saito K, et al. Leiomyosarcoma of the ovarian vein with the renal vein invasion: a case report. Nihon Hinyokika Gakkai Zasshi. 2017;108:210–4 [in Japanese].
13. Cho HJ, Kim HK, Suh JH, Lee GL, Shim JC, Kim YH, et al. Leiomyosarcoma of the ovarian vein: a case report with radiological findings. Korean J Radiol. 2008;9(Suppl)514–7.
14. Inatsu H, Murata T, Tokunaga M, Nyomura S, Nakahashi N, Kondo Y, et al. Leiomyosarcoma arising from ovarian vein with right hydrenephrosis: a case report. Nihon Hinyokika Gakkai Zasshi. 2015;106:211–5 [in Japanese].
15. Matsuzono T, Chan CY, Chan MY. Gonadal vein leiomyosarcoma: a case report with radiological findings. Intracranial Rare Dis. 2015;4:152–4.
16. Tsuchiya H, Kawaiara T, Kawa K, Chihara I, Tanaka K, Kinura T, et al. A case of leiomyosarcoma arising from the ovarian vein preoperatively diagnosed with radiological imaging. Hinyokika Kyyo. 2017;63:407–12 [in Japanese].
17. López-Ruiz ME, Yébenes L, Berjón A, Hardisson D. Primary leiomyosarcoma of the ovarian vein: case report and literature review. Int J Surg Pathol. 2017;25:339–43.
18. Bautista N, Xu W, O’Connell TX. Retroperitoneal soft-tissue sarcomas: prognosis and treatment of primary and recurrent disease. Am Surg. 2000;66:832–6.
19. Brotan PN Jr, Orvis BR, Hricak H, Egeter DA, Tanagho EA. Assessment of a retroperitoneal mass by magnetic resonance imaging in a 65-year-old woman. J Urol. 1986;136:71–5.
20. Gage MJ, Patel AV, Koenig KL, Newman E. Non-vena cava venous leiomyosarcomas: a review of the literature. Ann Surg Oncol. 2012;19:3368–74.
21. Hartman DS, Hayes WS, Choyke PL, Tillettts GP. Leiomyosarcoma of the retroperitoneum and inferior vena cava: radiologic-pathologic correlation. Radiographics. 1992;12:1203–20.
22. Sessa B, Iannicelli E, Caterino S, D’Angelo F, Millone M, Ziparo V, et al. Imaging of leiomyosarcoma of the inferior vena cava: comparison of 2 cases and review of the literature. Cancer Imaging. 2010;10:890–4.
23. Yoshida Y, Kurokawa T, Sawamura Y, Shinagawa A, Tsujikawa T, Okazawa H, et al. Comparison of 18F-FDG PET and MRI in assessment of uterine smooth muscle tumors. J Nucl Med. 2008;49:708–12.
24. Dalalins I. Vascular smooth muscle tumors: review of the literature. Int J Surg. 2008;65:157–63.
25. Ezrench D, Sencar M, Novak J. Retropertitoneal sarcoma: 25 years of experience with aggressive surgical treatment at the Institute of Oncology, Ljubljana. J Surg Oncol. 2005;91:1–9.
26. Bradley JC, Caplan R. Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas. Am Surg. 2002;6852–6.
27. Albertemeier M, Roach A, Roeder F, Hasenhüttl S, Pratschke S, Kirschneck M, et al. External beam radiation therapy for resectable soft tissue sarcoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25:754–67.
28. Pasquali S, Gronchi A. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9:415–29.
29. Abdelfatah E, Guzzetta AA, Nagaranj N, Wolfgang CL, Pawlik TM, Choti MA, et al. Long-term outcomes in treatment of retroperitoneal sarcomas: a 15 year single-institution evaluation of prognostic features. J Surg Oncol. 2016;114:56–64.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.